Document Detail


Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study.
MedLine Citation:
PMID:  23336594     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To evaluate the effects the administration of myo-inositol (MYO) on hormonal parameters in a group of polycystic ovary syndrome (PCOS) patients.
DESIGN: Controlled clinical study.
SETTING: PCOS patients in a clinical research environment.
PATIENTS: 50 overweight PCOS patients were enrolled after informed consent.
INTERVENTIONS: All patients underwent hormonal evaluations and an oral glucose tolerance test (OGTT) before and after 12 weeks of therapy (Group A (n¼10): MYO 2 g plus folic acid 200 mg every day; Group B (n¼10): folic acid 200 mg every day). Ultrasound examinations and Ferriman-Gallwey score were also performed.
MAIN OUTCOME MEASURES: Plasma LH, FSH, PRL, E2, 17OHP, A, T, glucose, insulin, C peptide concentrations, BMI, HOMA index and glucose-to-insulin ratio.
RESULTS: After 12 weeks of MYO administration plasma LH, PRL, T, insulin levels and LH/FSH resulted significantly reduced. Insulin sensitivity, expressed as glucose-to-insulin ratio and HOMA index resulted significantly improved after 12 weeks of treatment. Menstrual cyclicity was restored in all amenorrheic and oligomenorrheic subjects. No changes occurred in the patients treated with folic acid.
CONCLUSIONS: MYO administration improves reproductive axis functioning in PCOS patients reducing the hyperinsulinemic state that affects LH secretion.
Authors:
P G Artini; O M Di Berardino; F Papini; A D Genazzani; G Simi; M Ruggiero; V Cela
Related Documents :
25204974 - Preserved beta-cell function in type 1 diabetes by mesenchymal stromal cells.
24477354 - Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with li...
15866064 - Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
6375614 - Gastrointestinal tract complications of diabetes mellitus. pathophysiology and management.
21273494 - Clinical significance of urinary liver-type fatty acid-binding protein in diabetic neph...
172204 - Pathways of carbohydrate metabolism in mycobacterium tuberculosis h37rv1.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2013-01-22
Journal Detail:
Title:  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology     Volume:  29     ISSN:  1473-0766     ISO Abbreviation:  Gynecol. Endocrinol.     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-03-12     Completed Date:  2013-08-30     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  8807913     Medline TA:  Gynecol Endocrinol     Country:  England    
Other Details:
Languages:  eng     Pagination:  375-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Glucose
Body Mass Index
C-Peptide / blood
Drug Therapy, Combination
Estradiol / blood
Female
Folic Acid / therapeutic use*
Follicle Stimulating Hormone / blood
Glucose Tolerance Test
Humans
Inositol / therapeutic use*
Insulin / blood
Insulin Resistance
Luteinizing Hormone / blood
Polycystic Ovary Syndrome / blood,  drug therapy*
Prolactin / blood
Testosterone / blood
Treatment Outcome
Chemical
Reg. No./Substance:
0/Blood Glucose; 0/C-Peptide; 0/Insulin; 3XMK78S47O/Testosterone; 4L6452S749/Inositol; 4TI98Z838E/Estradiol; 9002-62-4/Prolactin; 9002-67-9/Luteinizing Hormone; 9002-68-0/Follicle Stimulating Hormone; 935E97BOY8/Folic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Health impacts of the July 2010 heat wave in Québec, Canada.
Next Document:  Quantitative proteomics-based analysis supports a significant role of GTG proteins in regulation of ...